Hide metadata

dc.date.accessioned2017-09-24T11:37:06Z
dc.date.available2017-09-24T11:37:06Z
dc.date.created2016-10-14T18:49:22Z
dc.date.issued2017
dc.identifier.citationPistone, Sara Goycoolea, Francisco M. Young, Alix Smistad, Gro Hiorth, Marianne . Formulation of polysaccharide-based nanoparticles for local administration into the oral cavity. European Journal of Pharmaceutical Sciences. 2017, 96, 381-389
dc.identifier.urihttp://hdl.handle.net/10852/58506
dc.description.abstractThe efficacy of treatments for oral ailments is often challenged by a low residence time of the conventional pharmaceutical formulations in the oral cavity. The residence time in the oral cavity could be improved by using bioadhesive formulations, such as preparations based on polysaccharides. This study describes the formulation and the evaluation of polysaccharide-based nanosystems as drug delivery systems addressed to the oral cavity. Nanoparticles based on chitosan, alginate or pectin were prepared through self-assembly by ionotropic gelation using oppositely charged crosslinkers (tripolyphosphate or zinc). Characteristics of nanoparticles at increasing crosslinker concentration provided the basis for selecting the most suitable formulations. The nanoparticles were tested for cytotoxicity against buccal cells (TR146) and for stability in a medium simulating pH, ionic strength, electrolyte composition and concentration of saliva. Alginate nanoparticles were the most stable in the salivary environment, while chitosan nanoparticles were the most cytocompatible. Alginate nanoparticles and pectin nanoparticles revealed possible cytotoxicity due to the presence of zinc. This knowledge is important in the early design of polymer-based nanoparticles for oral usage and for potential improving of the biocompatibility of the investigated nanoparticles with the oral environment.en_US
dc.languageEN
dc.publisherElsevier Science
dc.titleFormulation of polysaccharide-based nanoparticles for local administration into the oral cavityen_US
dc.typeJournal articleen_US
dc.creator.authorPistone, Sara
dc.creator.authorGoycoolea, Francisco M.
dc.creator.authorYoung, Alix
dc.creator.authorSmistad, Gro
dc.creator.authorHiorth, Marianne
cristin.unitcode185,15,23,0
cristin.unitnameFarmasøytisk institutt
cristin.ispublishedtrue
cristin.fulltextpostprint
cristin.qualitycode2
dc.identifier.cristin1391929
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European Journal of Pharmaceutical Sciences&rft.volume=96&rft.spage=381&rft.date=2017
dc.identifier.jtitleEuropean Journal of Pharmaceutical Sciences
dc.identifier.volume96
dc.identifier.startpage381
dc.identifier.endpage389
dc.identifier.doihttp://dx.doi.org/10.1016/j.ejps.2016.10.012
dc.identifier.urnURN:NBN:no-61223
dc.type.documentTidsskriftartikkelen_US
dc.type.peerreviewedPeer reviewed
dc.source.issn0928-0987
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/58506/2/AcceptedmanuscriptafterrevisionSaraPistone.pdf
dc.type.versionAcceptedVersion


Files in this item

Appears in the following Collection

Hide metadata